...
首页> 外文期刊>Developmental Immunology: Journal of Immunology Research >Allergenic Characterization of New Mutant Forms of Pru p 3 as New Immunotherapy Vaccines
【24h】

Allergenic Characterization of New Mutant Forms of Pru p 3 as New Immunotherapy Vaccines

机译:Pru p 3的新突变形式作为新的免疫治疗疫苗的致敏特性。

获取原文
           

摘要

Nowadays, treatment of food allergy only considered the avoidance of the specific food. However, the possibility of cross-reactivity makes this practice not very effective. Immunotherapy may exhibit as a good alternative to food allergy treatment. The use of hypoallergenic molecules with reduced IgE binding capacity but with ability to stimulate the immune system is a promising tool which could be developed for immunotherapy. In this study, three mutants of Pru p 3, the principal allergen of peach, were produced based on the described mimotope and T cell epitopes, by changing the specific residues to alanine, named asPru p 3.01, Pru p 3.02, andPru p 3.03.Pru p 3.01showed very similar allergenic activity as the wild type byin vitroassays. However,Pru p 3.02andPru p 3.03presented reduced IgE binding with respect to the native form, byin vitro,ex vivo,and in vivo assays. In addition,Pru p 3.03had affected the IgG4 binding capacity and presented a random circular dichroism, which was reflected in the nonrecognition by specific antibodies anti-Pru p 3. Nevertheless, bothPru p 3.02andPru p 3.03maintained the binding to IgG1 and their ability to activate T lymphocytes. Thus,Pru p 3.02andPru p 3.03could be good candidates for potential immunotherapy in peach-allergic patients.
机译:如今,对食物过敏的治疗仅考虑避免使用特定食物。但是,交叉反应的可能性使这种做法不是很有效。免疫疗法可以替代食物过敏治疗。具有降低的IgE结合能力但具有刺激免疫系统能力的低变应原性分子的使用是可以为免疫疗法开发的有前途的工具。在这项研究中,通过将特定的残基更改为丙氨酸,将桃的主要变应原Pru p 3的三个突变体基于所述的拟表位和T细胞表位产生,分别命名为Pru p 3.01,Pru p 3.02和Pru p 3.03。通过体外测定,Pru p 3.01显示出与野生型非常相似的变应原活性。然而,通过体外,离体和体内测定,Pru p 3.02和Pru p 3.03相对于天然形式表现出降低的IgE结合。另外,Pru p 3.03影响了IgG4的结合能力并呈现出随机的圆二色性,这反映在抗Pru p 3特异性抗体的不识别中。然而,Pru p 3.02和Pru p 3.03都保持了与IgG1的结合及其能力。激活T淋巴细胞。因此,Pru p 3.02和Pru p 3.03可能是桃类过敏患者潜在免疫疗法的良好候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号